Combined antiviral treatment in HIV infection. Is it value for money?
- 1 November 1999
- journal article
- Published by Elsevier in Public Health
- Vol. 113 (6) , 315-317
- https://doi.org/10.1016/s0033-3506(99)00188-2
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- British HIV Association guidelines for antiretroviral treatment of HIV seropositive individualsThe Lancet, 1997
- Viral Counts Count in HIV InfectionScience, 1996
- A Comparison of Immediate with Deferred Zidovudine Therapy for Asymptomatic HIV-Infected Adults with CD4 Cell Counts of 500 or More per Cubic MillimeterNew England Journal of Medicine, 1995
- Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral TherapyAnnals of Internal Medicine, 1995
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- The Duration of Zidovudine Benefit in Persons With Asymptomatic HIV InfectionJAMA, 1994
- A Comparative Trial of Didanosine or Zalcitabine after Treatment with Zidovudine in Patients with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1994
- A Controlled Trial Comparing Continued Zidovudine with Didanosine in Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1992
- Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987